| Identification | Back Directory | [Name]
SR-18292 | [CAS]
2095432-55-4 | [Synonyms]
SR-18292
SR 18292;SR18292
SR-18292; SR 18292; SR18292
2-Propanol, 1-[(1,1-dimethylethyl)[(4-methylphenyl)methyl]amino]-3-(1H-indol-4-yloxy)- | [Molecular Formula]
C23H30N2O2 | [MOL File]
2095432-55-4.mol | [Molecular Weight]
366.5 |
| Chemical Properties | Back Directory | [Boiling point ]
553.6±50.0 °C(Predicted) | [density ]
1.132±0.06 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMF: 25 mg/ml; DMSO: 25 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml; Ethanol: 10 mg/ml | [form ]
A crystalline solid | [pka]
13.90±0.20(Predicted) | [color ]
White to light brown |
| Hazard Information | Back Directory | [Uses]
SR 18292 is a novel selective inhibitor of PGC-1alpha Gluconeogenic Activity. | [Biological Activity]
SR-18292 is a potent and specific inhibitor of hepatic gluconeogenesis via increased acetylation of PGC-1α and suppression of gluconeogenic gene expression. SR-18292 reduces blood glucose and increases hepatic insulin sensitivity in mouse models of T2D. | [in vivo]
SR-18292 reduces fasting blood glucose, increases hepatic insulin sensitivity and improves glucose homeostasis in diabetic mice. The high fat diet (HFD) fed mice, a dietary model of obesity and T2D, are treated with SR-18292 (45mg/kg) via I.P. injection for 3 consecutive days and again on day 4 before measuring fasting blood glucose. Strikingly, mice that are treated with SR-18292 have significantly lower levels of fasting blood glucose concentrations compared to matched vehicle-treated control mice. The induction of gluconeogenic gene expression is a regulatory component of the response to fasting. Importantly, gluconeogenic gene expression, specifically that of Pck1, is inhibited in livers isolated from mice treated with SR-18292[1]. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|